Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 18/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3099458 | 1.00 | EGFR (0.54) | EGFRHDAC1HDAC4MEF2DHDAC3 | |
| SCHEMBL3101676 | 0.94 | HDAC1 (0.56) | EGFRHDAC1HDAC4MEF2DHDAC3 | |
| SCHEMBL3101688 | 0.94 | HDAC1 (0.56) | EGFRHDAC1HDAC4MEF2DHDAC3 | |
| SCHEMBL3099541 | 0.91 | HDAC1 (0.62) | EGFRHDAC1HDAC4HDAC3HDAC8 | |
| SCHEMBL3099557 | 0.91 | HDAC1 (0.62) | EGFRHDAC1HDAC4HDAC3HDAC8 | |
| SCHEMBL3098895 | 0.91 | HDAC4 (0.54) | HDAC1HDAC4MEF2DHDAC3HDAC8 | |
| SCHEMBL3098908 | 0.91 | HDAC4 (0.54) | HDAC1HDAC4MEF2DHDAC3HDAC8 | |
| SCHEMBL8028900 | 0.90 | EGFR (0.56) | EGFRHDAC1HDAC4MEF2DHDAC2 | |
| SCHEMBL3102644 | 0.87 | HDAC1 (0.60) | EGFRHDAC1HDAC4MEF2DHDAC3 | |
| SCHEMBL3102633 | 0.87 | HDAC1 (0.60) | EGFRHDAC1HDAC4MEF2DHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2238103-A1 | NOVEL N-(2-AMINO-PHENYL)-AMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2010-10-13 | — | — | EP | disclosed |
| US-7795315-B2 | N-(2-amino-phenyl)-amide derivatives | HOFFMAN-LA ROCHE INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090203681-A1 | NOVEL N-(2-AMINO-PHENYL)-AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-13 | — | — | US | disclosed |
| WO-2009095324-A1 | NOVEL N-(2-AMINO-PHENYL)-AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203681-A1 | NOVEL N-(2-AMINO-PHENYL)-AMIDE DERIVATIVES | MKI67, API5, BAD | EGFR 652/4885HDAC1 815/4885HDAC4 1003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.